- Reports: ESI may start 'price war' over new hepatitis C drugs
- Newly approved hepatitis C treatment by Gilead Sciences said to offer major advance in treatment
- Mylan tapped as Gilead's exclusive business partner for India
- Crossmark names Janet Carter-Smith VP
- Gilead's Complera approved for HIV patients already on stable drug regimens
FOSTER CITY, Calif. — Drug maker Gilead Sciences will acquire Pharmasset for $11 billion, or $137 per share, Gilead said Monday.
Pharmasset, based in Princeton, N.J., is a drug maker that currently has three treatments for hepatitis C undergoing clinical trials, including PSI-7977, which is in late-stage development.
"The acquisition of Pharmasset represents an important and exciting opportunity to accelerate Gilead's effort to change the treatment paradigm for HCV-infected patients by developing all-oral regimens for the treatment of the disease, regardless of viral genotype," Gilead chairman and CEO John Martin said. "Pharmasset presented compelling phase-2 data earlier this month further characterizing the strong efficacy and safety profile of PSI-7977."